By Spondylitis Association of America
Monday, April 09, 2018
The following is an announcement from SAA about a third party clinical trial. SAA is not affiliated with this study, the researchers, or the drug manufacturer.
A phase 2/3 clinical trial is now recruiting patients over the age of 18 with active ankylosing spondylitis (AS) to participate in a study evaluating the safety and efficacy of Upadacitinib (ABT- 494) - a JAK inhibitor medication taken orally.
The purpose of the trail, titled, “A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis” is to investigate the effectiveness, impact and performance of Upadacitinib by comparing the perceived symptomatic improvements in pain, global assessment, function, and inflammation experienced with Upadacitinib versus a placebo (a mock medication with no therapeutic effects.)
Study qualifications include:
More information can be found on the Clinical Trials website.
This study is sponsored by AbbVie, who has created a promotional website for the study. You’ll find additional information and a qualification questionnaire at http://clinicalresearchstudy4as.com/.
For location of study centers, you can call (847) 283-8955, email firstname.lastname@example.org or visit the clinical trials study locations page.
Learn more about participating in Clinical Studies
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.